Meeting
2023 ASCO Genitourinary Cancers Symposium
Association of primary tumor radiomic phenotypes and outcomes in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) treated with cytoreductive nephrectomy (CN).
Authors
Mateus Trinconi Cunha
Instituto do Câncer do Estado de São Paulo, University of São Paulo, São Paulo, Brazil
Mateus Trinconi Cunha , Lucas Stangler , Pedro Freire , Paulo Victor Alves Pinto , Fernando Morbeck Almeida Coelho , Públio Viana , Mauricio Cordeiro , William Carlos Nahas , Jose Mauricio Mota
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Diagnostics and Imaging
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 622)
DOI
10.1200/JCO.2023.41.6_suppl.622
Abstract #
622
Poster Bd #
E12
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immunotherapy: A systematic review and meta-analysis.
First Author: Fengnian Zhao
Poster
2020 ASCO Virtual Scientific Program
Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma.
First Author: Shaan Dudani
Poster
2019 Genitourinary Cancers Symposium
Sites of metastasis (mets) and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
First Author: Dylan J Martini
Poster
2019 Genitourinary Cancers Symposium
Effect of immunotherapy (IO) on primary renal tumor in metastatic renal cell cancer (mRCC).
First Author: Antoine Jamet